Real Medicine Means Saying No Sometimes

A clinic that prescribes to everyone who applies is not practicing medicine. It is running an approval operation. The word "medicine" implies clinical judgment — and clinical judgment, exercised honestly, sometimes produces a decision to not prescribe. If that decision is never made, judgment is not being exercised. Something else is.

This is worth stating clearly because the commercial incentive in subscription healthcare points entirely in the opposite direction. Every approval is revenue. Every decline is a customer lost. In a model built on subscription growth, the financial pressure is to approve as many applicants as possible, to maintain as many active subscriptions as possible, and to minimize any clinical interaction that might produce a reason to stop or delay treatment. This is not medicine. It is commerce wearing medicine's clothing.

When IHA Says No

There are patients for whom GLP-1 therapy is not appropriate right now. Active thyroid conditions that have not been stabilized. A personal or family history of medullary thyroid carcinoma or MEN2. Medications that contraindicate GLP-1 use. Gastrointestinal conditions that would make the side effects disproportionately risky. Patients who present with goals or expectations that the treatment cannot realistically deliver — and for whom proceeding would be setting up a failure that damages trust in a treatment they might otherwise benefit from under different circumstances.

There are patients for whom bioidentical hormone replacement therapy is not appropriate right now. Active estrogen-sensitive conditions that require specialist management first. Hormone-sensitive malignancy history that changes the risk-benefit calculation. Unresolved liver conditions that affect hormone metabolism. Significant cardiovascular risk factors that need to be addressed before hormonal intervention is appropriate.

What a Decline Actually Looks Like

When IHA declines a patient, it is not an automated rejection. It is a physician communicating a specific clinical reason and, where possible, a path forward. This might mean: "Your thyroid panel shows X; once you have worked with an endocrinologist to address that, GLP-1 therapy may be appropriate and we're happy to revisit." Or: "Your history of Y means BHRT requires a different risk conversation — let's discuss what that looks like for you specifically."

This is a different kind of value than an approval. An approval gets you started. A thoughtful decline keeps you safe and gives you a roadmap. Both are examples of medicine. Only one of them is commercially incentivised.

The Trust Equation

There is a practical reason to want your healthcare provider to be capable of saying no. If your provider approves everyone, you cannot trust that your approval means anything — that it reflects a genuine clinical assessment of your situation rather than an automated step in a subscription flow. You cannot be confident that the dose you received is yours rather than everyone's. You cannot know whether the ongoing prescription is clinically monitored or just renewing.

When a practice demonstrates that it can decline — that it has done so and will do so — you know that the approval you received was earned. That the physician who signed your prescription reviewed your history and reached a considered decision. That the treatment you are receiving reflects your biology, your risk profile, and a clinician's judgment applied to your specific situation. That is what trust in medical care requires.

IHA's initial consultation is a genuine clinical review. Physician-directed assessment means that the decision made at the end of it — whether to proceed with GLP-1 therapy, BHRT, or a combination — is a medical decision, not an approval workflow. For patients who are appropriate candidates, that is a meaningful assurance. For those who are not, it is the beginning of a more useful conversation than an automated sign-up.

The Specific Clinical Reasons IHA Declines

Transparency about when and why a practice declines patients is itself a marker of clinical integrity — because it demonstrates that the practice has a clinical framework for those decisions rather than a commercial default to approval. At IHA, the categories of patients for whom we will not immediately proceed with treatment include the following.

For GLP-1 therapy: patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), for whom GLP-1 receptor agonists are contraindicated. Patients with active pancreatitis, severe GI dysmotility, or Crohn's disease where the mechanism of GLP-1 therapy would create unacceptable additional burden. Patients on medications with significant interactions, particularly certain diabetes medications where combining with semaglutide requires specialist diabetes management. Patients with poorly controlled thyroid disease, where stabilization should precede any metabolic intervention.

For BHRT: patients with estrogen-sensitive malignancy history — specifically estrogen receptor-positive breast cancer — where hormone therapy requires the involvement of the oncologist who managed that care, not just a general telehealth prescriber. Patients with active unprovoked venous thromboembolism or known thrombophilia where the clotting risk conversation requires specialist haematological input. Patients with hepatic impairment that significantly affects hormone metabolism. Patients with unresolved vaginal bleeding where investigation must precede rather than follow any hormonal intervention.

When "Not Now" Is the Most Useful Answer

The decline categories above share a common feature: they are not permanent. They are clinical situations that require resolution before treatment is appropriate — not bars that permanently exclude a patient from care. A woman with incompletely evaluated postmenopausal bleeding is declined for BHRT not because she is not a candidate, but because starting hormone therapy before identifying the cause of the bleeding could mask a significant finding. Once the evaluation is complete and the cause identified — often benign, sometimes not — the BHRT conversation is available.

A woman with inadequately controlled thyroid disease is declined for GLP-1 therapy not because the two are incompatible, but because optimizing thyroid function first produces a cleaner treatment picture and better outcomes. Once her thyroid status is stable, the metabolic picture is clearer and the GLP-1 program can be designed appropriately for her actual physiology rather than her thyroid-confounded physiology.

This is what clinical judgment looks like in practice: a physician who understands enough about the patient's full picture to know what should happen in what order — and who has the integrity to delay the commercial transaction in the patient's interest. A subscription service that has no mechanism for this kind of sequential clinical reasoning — that cannot say "first address X, then come back for Y" — is not equipped to serve patients whose situations have any complexity at all.

What You Learn From a Decline

A patient who is declined by IHA leaves the consultation with specific clinical information: here is why treatment is not appropriate right now, here is what condition needs to be met before that changes, and here is what we would recommend as the next step in your care. This is more useful clinical information than an approval would have been, had the approval been made without properly assessing the picture.

It is also information that a subscription service cannot provide — because the subscription service has no mechanism for the assessment that would generate it. A patient who applies to a prescription farm and is approved has learned nothing about whether treatment is appropriate for her. She has learned only that she met the criteria for a subscription. These are not the same thing, and the difference matters most for the patients whose situations have the complexity that responsible clinical assessment is designed to identify.

IHA's initial consultation is a genuine clinical evaluation conducted by a physician who is accountable for the outcome. The result of that evaluation — whether it is an approval for BHRT, for GLP-1 therapy, for both, or for neither right now — is a medical decision. That is not a lower standard than approval. It is a higher one.

The Difference Between 'Not Now' and 'Never': How IHA Communicates

A decline from a clinical practice is not equivalent to a rejection from a subscription service, and the difference lies almost entirely in what the patient receives on the other side of that decision. Understanding what clinical communication should look like when a woman is not an immediate candidate for treatment clarifies both the value of a real medical evaluation and the practical pathway forward for women who have been told "not now."

When IHA declines a patient — whether for BHRT due to a clinical contraindication, for GLP-1 therapy due to a medical history that changes the risk-benefit calculation, or for any other clinical reason — the patient receives a specific clinical reason, not a denial code or a form rejection. The reason is tied to the specific clinical finding: an elevated blood pressure that needs to be addressed before GLP-1 therapy can be safely initiated; a personal history of hormone-sensitive malignancy that requires oncology clearance before BHRT can be considered; a thyroid abnormality that needs primary care management before hormonal optimization can proceed appropriately. Vague language ("you are not a candidate at this time") without a specific clinical explanation is not adequate — it leaves the patient with no actionable information and no path forward.

The specific next step is the second component of a real clinical decline. Telling a patient that her blood pressure needs to be controlled before GLP-1 therapy is clinically responsible, but it is incomplete without a clear recommendation: a referral to her primary care provider with a specific request (blood pressure evaluation and management, with a target range for reconsideration), or a recommendation for a specific diagnostic workup, or a timeframe after which reassessment is clinically appropriate. A clinical decline without a next step is a dead end. A clinical decline with a specific next step is a sequenced plan.

Referrals are a meaningful component of this communication. When IHA declines a patient due to a clinical finding that requires management by a different specialty — an abnormal thyroid panel that warrants endocrinology evaluation, a cardiovascular risk marker that warrants cardiology review, an abnormal breast imaging result that warrants surgical oncology consultation — the referral is specific and documented. The patient is not left to navigate the healthcare system independently without clinical guidance. The referral is part of the clinical communication, not an afterthought appended after the decline.

How this differs from a subscription service's refusal is structural, not stylistic. A subscription service that declines a patient does so through an automated or semi-automated process that applies a set of exclusion criteria without physician review. The patient receives a notification that she does not qualify, often without a specific reason, and without a clinical pathway to address the excluding factor. There is no physician who reviewed her case, no clinical finding documented in her record, and no next step provided because no clinical assessment occurred. The process is a screening filter, not a medical evaluation. The patient may be left believing that she has been evaluated and found unsuitable, when in fact she has been screened out by an algorithm and has not been evaluated by a physician at all.

Women who were initially declined by IHA and later approved — after completing the recommended workup, addressing the flagged clinical concern, or following up with the indicated referral — consistently describe the sequential process as clinically valuable rather than merely frustrating. The period between initial decline and approval gave them clinical information about their health that they did not have before: a blood pressure issue they had underestimated, a thyroid abnormality that had been subclinical, a metabolic finding that their primary care provider had not acted on. The "not now" was not a barrier — it was a diagnostic step that identified something that needed to be addressed and would have been relevant to their long-term health regardless of the hormone or weight loss intervention. That is what a clinical evaluation is supposed to produce: information that is useful to the patient's health, not just to the business relationship.

For women who are uncertain whether their clinical situation would result in a decline or an approval, the most direct path is a clinical consultation that reviews the specific history rather than a self-assessment based on general exclusion criteria. The post on how to tell if your hormone clinic is practicing medicine provides additional context for evaluating any clinical process, including IHA's. If you want to understand how your specific clinical picture interacts with the treatment options, starting that conversation is the appropriate first step — and a real clinical response to your situation is what you should expect to receive, whether that response is a treatment protocol or a clearly explained next step toward becoming a candidate.

The clinical value of the sequential process — assessment, decline with explanation, workup, reassessment, approval — is that it produces a better-informed patient and a more precisely calibrated protocol. A woman who was declined because of an elevated fasting glucose that her PCP then evaluated and managed has entered the hormone program with better metabolic baseline data than if she had been approved immediately without that clinical detour. A woman whose thyroid abnormality was identified during the intake panel and referred to endocrinology has a thyroid condition under management that improves her hormonal health outcomes across the board. The "not now" was not a delay — it was a clinical step that improved the quality of the eventual "yes." This is what clinical gatekeeping produces when it is functioning correctly: not just a safer patient population in the program, but a better clinical foundation for each patient who eventually enters it. The distinction between that process and a rejection-without-explanation from a subscription service is not a matter of bedside manner. It is a matter of whether a clinical assessment occurred at all.

What Hearing 'No' in a Clinical Context Actually Means

The experience of being told by a clinical team that a specific treatment is not appropriate — or that the dosing you were expecting is not what the evidence supports for your situation — is uncomfortable in the moment. In retrospect, it is almost always the thing that patients are most grateful for. A clinical relationship in which your physician is willing to slow down, explain a concern, recommend an alternative, or defer a decision pending additional information is a relationship in which you can trust the 'yes' that follows the willingness to say 'no.'

IHA's approach to clinical decision-making reflects this principle throughout the treatment arc. The initial assessment may conclude that GLP-1 therapy is not the right starting point for a specific patient — that the hormonal picture needs to be addressed first, or that there is a contraindication to consider. The monitoring at eight weeks may result in a dose change that is lower than the patient expected. The six-month review may recommend adding a component that was not part of the original plan. Each of these adjustments reflects a clinical relationship that is actively managing your outcomes rather than processing your subscription. That clinical relationship begins with the initial consultation — and its value is most apparent in the moments when the honest clinical answer is more complex than a simple approval.